Cervical adenocarcinoma
MONDO:0005153An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type.
Also known as: adenocarcinoma - cervix, adenocarcinoma of cervix, adenocarcinoma of cervix uteri, adenocarcinoma of the cervix, adenocarcinoma of the cervix uteri, adenocarcinoma of the uterine cervix, adenocarcinoma of uterine cervix, cervical adenocarcinoma
2882 clinical trials for this condition and its sub-types, 27 tagged with Cervical adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Cervical adenocarcinoma
-
Cervical adenosquamous carcinoma 16 trials
1 sub-type
-
Cervical clear cell adenocarcinoma 4 trials
1 sub-type
-
Endocervical adenocarcinoma 3 trials
-
Wolffian duct adenocarcinoma 2 trials
-
Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types
6 sub-types
- Endocervical type cervical mucinous adenocarcinoma 1 trial
- Cervical mucinous adenocarcinoma, minimal deviation variant 0 trials
- Cervical villoglandular adenocarcinoma 0 trials
- Intestinal variant cervical mucinous adenocarcinoma 0 trials
- Signet ring cell variant cervical mucinous adenocarcinoma 0 trials
- Uterine ligament mucinous adenocarcinoma 0 trials
-
Cervical adenoid cystic carcinoma 0 trials
-
Cervical endometrioid adenocarcinoma 0 trials
1 sub-type
-
Cervical serous adenocarcinoma 0 trials
1 sub-type
-
Uterine ligament adenocarcinoma 0 trials
4 sub-types
-
Immunotherapy drug nivolumab tested against tough cervical cancers
Disease control OngoingThis phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a triple therapy beat cervical cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug triapine to standard radiation and cisplatin improves survival in women with advanced cervical or vaginal cancer. About 450 participants receive either standard treatment or standard treatment plus triapine. The study aims to see i…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental drug combo shows promise for Tough-to-Treat gynecologic cancers
Disease control OngoingThis early-phase study tested an oral drug called triapine added to standard chemotherapy (cisplatin) and radiation for people with advanced cervical or vaginal cancer. The main goals were to find the safest dose and check how well the body absorbs the drug. Twenty-one participan…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Custom immune cells take on multiple cancers in early trial
Disease control OngoingThis early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…
Phase 1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can yoga ease cervical cancer treatment? small trial aims to find out
Symptom relief OngoingThis study tests whether yoga therapy can improve physical and emotional well-being in people with cervical cancer undergoing chemotherapy and radiation. About 40 participants with stage IB2 to IIIB cervical cancer will attend yoga classes or receive a DVD. The main goal is to se…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New study aims to personalize cervical cancer treatment after radiation
Knowledge-focused OngoingThis study follows 60 people with cervical adenocarcinoma to see how their tumors respond to radiotherapy. Researchers will use imaging and tissue samples to better predict outcomes and guide next steps, like surgery or additional treatment. The goal is to improve monitoring and …
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:13 UTC